MedTrace Logo

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

NCT05970666 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2024-02-28

No results posted yet for this study

Summary

To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma

Conditions

Interventions

DRUG

TACE with adebrelimab and bevacizumab

TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    collaborator INDUSTRY

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Principal Investigators

  • Jianbo Chen · The First Affiliated Hospital of Xiamen University

  • Feng Ye · The First Affiliated Hospital of Xiamen University

  • congren Wang · Quanzhou First Hospital

  • Qinghe Cai · Affiliated Hospital of Putian University

  • Jiafei Chen · Putian First Hospital

  • Yongzhong Wang · Sanming Second Hospital

  • Feng Lin · Ningde Mindong Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2026-11-15
Completion
2026-11-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05970666 on ClinicalTrials.gov